Advantage Alpha Capital Partners LP Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advantage Alpha Capital Partners LP lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 48.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,050 shares of the biopharmaceutical company's stock after selling 12,146 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in Catalyst Pharmaceuticals were worth $272,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Steward Partners Investment Advisory LLC purchased a new position in Catalyst Pharmaceuticals during the fourth quarter worth approximately $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC boosted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $65,000. Finally, KBC Group NV grew its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Hedge funds and other institutional investors own 79.22% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Stock Down 0.6 %

NASDAQ:CPRX traded down $0.15 on Friday, reaching $24.69. 937,935 shares of the company's stock were exchanged, compared to its average volume of 1,113,694. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of 20.92, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16. The business has a fifty day moving average of $22.66 and a 200-day moving average of $21.80.

Analysts Set New Price Targets

CPRX has been the topic of several analyst reports. Bank of America reaffirmed a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Finally, Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.